Novel therapeutics categorized by pharmacologic class and target of interaction.
| Mechanism Modulated (Pharmacologic Class) . | Agent . |
|---|---|
| Survival Signals | |
| Antiangiogenic | thalidomide (Thalomid™) CC5013 (Revimid™), CC1088 bevacizumab (Avastin™) arsenic trioxide (Trisenox™) |
| Receptor tyrosine kinase inhibitors | SU5416, SU11248 PTK787 AG13736 imatinib mesylate (Gleevec™) |
| Protein kinase C inhibitor | PKC412 |
| Matrix metalloprotease inhibitor | AG3340 (Prinomastat™) |
| Farnesyl transferase Inhibitors | R115777 (Zarnestra™) SCH66336 (lonafarnib; Sarasar™) |
| Genetic Integrity | |
| Immunoconjugate | gemtuzumab ozogamicin (Mylotarg™) |
| P-glycoprotein antagonist | cyclosporine-A quinine sulfate LY335979 (zosuquidar trihydrochloride) |
| Mechanism Modulated (Pharmacologic Class) . | Agent . |
|---|---|
| Survival Signals | |
| Antiangiogenic | thalidomide (Thalomid™) CC5013 (Revimid™), CC1088 bevacizumab (Avastin™) arsenic trioxide (Trisenox™) |
| Receptor tyrosine kinase inhibitors | SU5416, SU11248 PTK787 AG13736 imatinib mesylate (Gleevec™) |
| Protein kinase C inhibitor | PKC412 |
| Matrix metalloprotease inhibitor | AG3340 (Prinomastat™) |
| Farnesyl transferase Inhibitors | R115777 (Zarnestra™) SCH66336 (lonafarnib; Sarasar™) |
| Genetic Integrity | |
| Immunoconjugate | gemtuzumab ozogamicin (Mylotarg™) |
| P-glycoprotein antagonist | cyclosporine-A quinine sulfate LY335979 (zosuquidar trihydrochloride) |